Alnylam Pharmaceuticals (ALNY) Gross Margin (2019 - 2025)
Historic Gross Margin for Alnylam Pharmaceuticals (ALNY) over the last 7 years, with Q3 2025 value amounting to 84.21%.
- Alnylam Pharmaceuticals' Gross Margin rose 5800.0% to 84.21% in Q3 2025 from the same period last year, while for Sep 2025 it was 80.65%, marking a year-over-year decrease of 61900.0%. This contributed to the annual value of 86.37% for FY2024, which is 10400.0% up from last year.
- According to the latest figures from Q3 2025, Alnylam Pharmaceuticals' Gross Margin is 84.21%, which was up 5800.0% from 81.64% recorded in Q2 2025.
- Alnylam Pharmaceuticals' Gross Margin's 5-year high stood at 89.8% during Q2 2024, with a 5-year trough of 133.94% in Q1 2025.
- Moreover, its 5-year median value for Gross Margin was 86.19% (2022), whereas its average is 73.95%.
- As far as peak fluctuations go, Alnylam Pharmaceuticals' Gross Margin skyrocketed by 134400bps in 2024, and later crashed by -2229000bps in 2025.
- Over the past 5 years, Alnylam Pharmaceuticals' Gross Margin (Quarter) stood at 86.99% in 2021, then dropped by -1bps to 86.22% in 2022, then decreased by -3bps to 83.63% in 2023, then dropped by -1bps to 82.69% in 2024, then increased by 2bps to 84.21% in 2025.
- Its Gross Margin was 84.21% in Q3 2025, compared to 81.64% in Q2 2025 and 133.94% in Q1 2025.